Observational studyMedicine2026
Stent-assisted coiling for ruptured anterior choroidal artery aneurysms: A retrospective observational study evaluating safety, efficacy, and antiplatelet strategies.
Observational study in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aneurysms of the anterior choroidal artery (AChA) are rare and pose treatment challenges due to eloquent adjacent anatomy and often complex morphology. This retrospective study evaluates the safety and efficacy of endovascular treatment, particularly stent-assisted coiling (SAC), for acutely ruptured AChA aneurysms, focusing on complications and antiplatelet management. We retrospectively analyzed 29 consecutive patients treated endovascularly within 72 hours of ictus. Patients were stratified by technique (coiling alone, n = 11 vs SAC, n = 18). Within the SAC cohort, 2 antiplatelet regimens were compared: dual antiplatelet therapy (DAPT, n = 7) versus intravenous tirofiban (n = 11). The primary outcome was a favorable clinical outcome (modified Rankin Scale: 0-2) at 6 months. No procedure-related mortality occurred. Periprocedural complication rates were comparable between groups (all P > .05). The overall rate of ischemic events (including intraoperative thrombosis and symptomatic infarction) was 27.8% (5/18) in the SAC group and 9.1% (1/11) in the coiling-alone group. Favorable clinical outcomes at 6 months were achieved in 90.9% of the coiling-alone group and 88.9% of the SAC group (discharge: 72.7% vs 77.8%). After inverse probability of treatment weighting adjustment, SAC was associated with an odds ratio of 1.13 (95% confidence interval [CI]: 0.14-9.09) for favorable outcome. The absolute risk reduction for recurrence was 27.3% (95% CI: 1.0%-53.6%), corresponding to number needed to treat = 3.7 (95% CI: 2.1-14.9). SAC demonstrated a trend toward higher complete occlusion (88.9% vs 63.6%; P = .16) and lower recurrence (0% vs 27.3%; P = .045; fragility index = 1). Within the SAC subgroup, no significant differences were observed between DAPT and tirofiban. Endovascular treatment, particularly SAC, appears to be a safe and feasible option for ruptured AChA aneurysms, with the potential for durable occlusion. However, given the small sample size and exploratory nature of this study, these findings should be considered hypothesis-generating and require confirmation in larger prospective cohorts. Both DAPT and tirofiban appear to be feasible antiplatelet strategies based on the limited data available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.